Welcome > Support > Âü°íÀÚ·á  
 
 
E
 
±Ûº¸±â
¼º¸í ÆÄ³ªÁø     (Date : 2010-09-14 11:15:58)
À̸ÞÀÏ info@panagene.com
Á¦¸ñ [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥]Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance.
³»¿ë

PNAÀÇ ÀåÁ¡ Áß Çϳª´Â SNP¸¦ ±¸ºÐÇÏ´Â ´É·ÂÀÌ Å¹¿ùÇÏ´Ù´Â °ÍÀÔ´Ï´Ù.
BÇü °£¿°À» ÀÏÀ¸Å°´Â HBVÀÇ °æ¿ì, µ¹¿¬º¯À̸¦ ÀÏÀ¸Å°¸ç ¿©·¯°¡Áö ¾àÁ¦¿¡ ´ëÇØ ³»¼ºÀ» °¡Áö°Ô µÇ¹Ç·Î, ÀûÀýÇÑ Ã³¹æÀ» À§ÇÏ¿© HBV ¹ÙÀÌ·¯½ºÀÇ µ¹¿¬º¯ÀÌ °ËÃâ±â¼úÀÌ ÇʼöÀûÀÔ´Ï´Ù.
(ÁÖ)ÆÄ³ªÁøÀº PNA ChipÀ» ÀÌ¿ëÇÏ¿© ¾àÁ¦ ³»¼ºÀ» ÀÏÀ¸Å°´Â HBVÀÇ µ¹¿¬º¯À̸¦ ³ôÀº ¹Î°¨µµ¿Í ƯÀ̵µ·Î °ËÃâÇÒ ¼ö ÀÖ´Â ±â¼úÀ» °³¹ßÇÏ¿´½À´Ï´Ù.


J Clin Microbiol. 2010 Sep;48(9):3127-31. Epub 2010 Jun 23.

Peptide nucleic acid array for detection of point mutations in hepatitis B virus associated with antiviral resistance.

Jang H, Kim J, Choi JJ, Son Y, Park H.

Panagene Inc., 816 Tamnip-Dong, Youseong-Gu, Daejeon, 305-510, South Korea.

Abstract

The detection of antiviral-resistant hepatitis B virus (HBV) mutations is important for monitoring the response to treatment and for effective treatment decisions. We have developed an array using peptide nucleic acid (PNA) probes to detect point mutations in HBV associated with antiviral resistance. PNA probes were designed to detect mutations associated with resistance to lamivudine, adefovir, and entecavir. The PNA array assay was sensitive enough to detect 10(2) copies/ml. The PNA array assay was able to detect mutants present in more than 5% of the virus population when the total HBV DNA concentration was greater than 10(4) copies/ml. We analyzed a total of 68 clinical samples by this assay and validated its usefulness by comparing results to those of the sequencing method. The PNA array correctly identified viral mutants and has high concordance (98.3%) with direct sequencing in detecting antiviral-resistant mutations. Our results showed that the PNA array is a rapid, sensitive, and easily applicable assay for the detection of antiviral-resistant mutation in HBV. Thus, the PNA array is a useful and powerful diagnostic tool for the detection of point mutations or polymorphisms.


Link to paper  => Click


 

 ¹øÈ£   Á¦¸ñ ÀÛ¼ºÀÚ ÆÄÀÏ Á¶È¸
   49           [³í¹®] [2016]Comparison of EGFR .. ÆÄ³ªÁø 32701
   48           [³í¹®] [2015]IDH Mutation Analys.. ÆÄ³ªÁø 65535
   47           [³í¹®] [2015]Low frequency of KR.. ÆÄ³ªÁø 44046
   46           [³í¹®] [2015]Simultaneous genoty.. ÆÄ³ªÁø 6643
   45           [³í¹®] [2014]Simultaneous diagno.. ÆÄ³ªÁø 26440
   44           [³í¹®] [2014]KRAS Mutation Detec.. ÆÄ³ªÁø 13783
   43           [³í¹®] [2013]Detection of EGFR m.. ÆÄ³ªÁø 1520
   42           [³í¹®] [2013]Detection and compa.. ÆÄ³ªÁø 6177
   41           [³í¹®] [2013]Detection of BRAF V.. ÆÄ³ªÁø 6557
   40           [³í¹®] [2013]Comparison of Direc.. ÆÄ³ªÁø 34998
   39           [³í¹®] [Microarray]Peptide nucle.. ÆÄ³ªÁø 20002
   38           [³í¹®] [Clamp]Rapid and Sensitiv.. ÆÄ³ªÁø 62686
   37           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] EGFR µ¹¿¬º¯.. ÆÄ³ªÁø 3823
   36           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] Development .. ÆÄ³ªÁø 49716
   35           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] JHDM3A modul.. ÆÄ³ªÁø 1592
   34           [³í¹®] [PNA Chip vs DNA Chip ÀÓ»ó.. ÆÄ³ªÁø 26229
   33           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥] PNA-mediated Re.. ÆÄ³ªÁø 17594
   32           [³í¹®] [ÆÄ³ªÁø Á¦Ç°»ç¿ë ³í¹®] ºñ¼Ò¼¼Æ÷Æó¾Ï¿¡.. ÆÄ³ªÁø 33417
   31           [³í¹®] [ÆÄ³ªÁø ³í¹® ¹ßÇ¥] PNA-Based Anti.. ÆÄ³ªÁø 4132
¢º           [³í¹®] [ÆÄ³ªÁø ³í¹®¹ßÇ¥]Peptide nucleic .. ÆÄ³ªÁø 4365
 

< 1 2 3 >